1.65
-0.02(-1.20%)
Currency In CAD
Address
27 Street Clair Avenue East
Toronto, ON M4T 2M5
Canada
Phone
647-428-7031
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
May 07, 2010
| Name | Title | Pay | Year Born |
| Mr. Richard Gabriel Muruve | Co-Founder, Chief Executive Officer, President & Director | 150,000 | 1971 |
| Mr. Aaron Benson | Director of Communications & Clinical Data Management | 0 | N/A |
| Mr. Andrew Bishop CFA | Chief Financial Officer & Director | 0 | 1966 |
| Dr. Daniel Abraham Muruve M.D. | Co-Founder, Chief Science Officer & Member of Scientific Advisory Board | 0 | N/A |
| Dr. Justin MacDonald Ph.D. | Co-Founder & Principal Scientist | 0 | N/A |
| Dr. Paul Beck | Co-Founder & Principal Scientist | 0 | N/A |
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.